Schizophrenia

The Pharmacy Times® Schizophrenia Resource Center is a comprehensive resource for clinical news and expert insights on treatments for schizophrenia.

Latest News

Mental health conditions, schizophrenia diagnosis and treatment with antipsychotic medication and psychotherapy. | Image Credit: Olivier Le Moal - stock.adobe.com

More Research Needed for Treatment of Clozapine-Resistant Schizophrenia

By Ashley Gallagher, Associate Editor

April 8th 2024

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Pharmacist working with a tablet computer in the pharmacy holding it in her hand while reading information | Image Credit: Dragana Gordic - stock.adobe.com

Community Pharmacists Can Help Monitor, Manage Cardiometabolic Parameters in Schizophrenia

By Alok Sharma, PhD

April 1st 2024

The Role of the Pharmacist in Long-Acting Injectable Therapies for Schizophrenia and Bipolar Disorder

By Alana Hippensteele, Managing Editor

March 24th 2024

Navigating Cannabis in Pharmacy Practice: State Legislation and Contraindications for Patient Use

By Alana Hippensteele, Managing Editor

March 23rd 2024

Credit: nobeastsofierce - stock.adobe.com

The Gut Microbiome Looks Different for People With Treatment-Resistant Schizophrenia

By Erin Hunter, Associate Editor

February 21st 2024

Latest CME Events & Activities

The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia

1.5 Credits / Neurology, Psychiatry

Managing Bipolar Disorder: The Pharmacist’s Role in Delivering Quality Care

1.0 Credits / Psychiatry

Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns

1.0 Credit / Law

Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications

1.5 Credits / Law, Oncology

Child Abuse: Responsibilities and Protection of the Reporter

1.0 Credit / Law

More News

FDA Approves Dexmedetomidine for Agitation From Bipolar Disorders, Schizophrenia

Ashley Gallagher, Associate Editor

April 7th 2022

BioXcel plans to launch Igalmi sublingual film in the United States in the second quarter of 2022.

Serious Mental Illness May Increase Risk of Heart Disease at Younger Ages

Ashley Gallagher, Associate Editor

March 24th 2022

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

FDA Approves sNDA for Rexulti for Adolescents With Schizophrenia

Ashley Gallagher, Associate Editor

January 10th 2022

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

Pharmacy Quiz: Test Your Knowledge on Schizophrenia

January 6th 2022

Ten quiz questions to assess your knowledge on common symptoms and treatments for schizophrenia.

Rates of Type 2 Diabetes Higher in People With Common Psychiatric Disorders

Jill Murphy, Associate Editor

December 21st 2021

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.

FDA Approves Lumateperone for the Treatment of Bipolar Depression

Aislinn Antrim, Assistant Managing Editor

December 20th 2021

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia

Skylar Kenney, Assistant Editor

November 16th 2021

The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.

<1 2